LOS ANGELES--(EON: Enhanced Online News)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Agile Therapeutics, Inc. (“Agile” or the “Company”) (Nasdaq: AGRX) concerning possible violations of federal securities laws.
“deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy and depression.”
If you purchased or otherwise acquired Agile shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
Agile is a pharmaceutical company that develops and markets prescription female contraceptive products.
On January 3, 2017, the Company revealed new data related to its Phase 3 SECURE study measuring Agile’s combined hormonal contraceptive patch product, Twirla. The FDA requested the study after it rejected Agile's first marketing application in 2013.
The Company stated that nearly 2% of study participants suffered "serious adverse events" including "deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy and depression." Furthermore, 51.4% of subjects dropped out of the study.
When this information was released to the public, the value of Agile stock fell almost 64%, causing investors severe harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.